Left atrial structure and function and the risk of death or heart failure in atrial fibrillation.


Journal

European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595

Informations de publication

Date de publication:
12 2019
Historique:
received: 01 07 2019
revised: 31 07 2019
accepted: 11 08 2019
pubmed: 30 11 2019
medline: 29 10 2020
entrez: 29 11 2019
Statut: ppublish

Résumé

The present study aimed to assess the association between left atrial (LA) structure and function and the risk for cardiovascular (CV) death or heart failure (HF) hospitalization in a population with atrial fibrillation (AF). In a prospective echocardiographic substudy of the Effective Anticoagulation with Factor Xa Next Generation in AF-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) study, 971 patients underwent transthoracic echocardiography. The associations between LA structure (LA volume index [LAVi]) and function (LA emptying fraction [LAEF] and LA expansion index [LAEi]) and risk for the composite endpoint of CV death or HF hospitalization, and its components, were assessed. Over a median follow-up of 2.5 years, 142 patients (14.6%) experienced CV death or HF hospitalization. Higher LAVi and lower LAEF and LAEi were each associated with a higher unadjusted risk for the composite outcome and its components. After adjustment for clinical and echocardiographic confounders, only measures of impaired LA function were predictive of the composite outcome (hazard ratio [HR] per 1 standard deviation [SD] decrease in LAEF: 1.35; 95% confidence interval [CI] 1.09-1.67 [P = 0.005]; HR per 1 SD decrease in LAEi: 1.34; 95% CI 1.06-1.69 [P = 0.012]). These findings were similar regardless of left ventricular ejection fraction, history of HF or whether patients were in AF or sinus rhythm at the time of the echocardiographic examination. In patients with AF, LA dysfunction was significantly associated with an increased risk for CV death or HF hospitalization and was more predictive of these outcomes than LA size. These parameters may help to identify AF patients at greatest risk for the development of HF. ClinicalTrials.gov, NCT00781391.

Identifiants

pubmed: 31777160
doi: 10.1002/ejhf.1606
pmc: PMC7321836
mid: NIHMS1581079
doi:

Banques de données

ClinicalTrials.gov
['NCT00781391']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1571-1579

Subventions

Organisme : NHLBI NIH HHS
ID : K23 HL128928
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL094301
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2019 The Authors. European Journal of Heart Failure © 2019 European Society of Cardiology.

Références

J Am Coll Cardiol. 2008 Jan 1;51(1):1-11
pubmed: 18174029
Circulation. 2016 Feb 2;133(5):484-92
pubmed: 26746177
Circulation. 2010 Sep 7;122(10):985-92
pubmed: 20733097
Eur Heart J. 2016 Oct 7;37(38):2893-2962
pubmed: 27567408
Eur Heart J Cardiovasc Imaging. 2012 Mar;13(3):227-34
pubmed: 22166594
Am J Med. 2015 Mar;128(3):260-7.e1
pubmed: 25446299
Eur J Heart Fail. 2016 Sep;18(9):1153-61
pubmed: 27349698
Eur J Heart Fail. 2016 Nov;18(11):1307-1320
pubmed: 27813305
Eur Heart J. 2009 Jan;30(1):56-65
pubmed: 19001474
Circulation. 2014 Feb 25;129(8):837-47
pubmed: 24345399
Am J Med. 2002 Oct 1;113(5):359-64
pubmed: 12401529
Am J Med. 2016 Aug;129(8):850-857.e2
pubmed: 26994510
Am Heart J. 2010 Oct;160(4):635-41
pubmed: 20934556
Circ Arrhythm Electrophysiol. 2017 Jan;10(1):
pubmed: 28077507
J Am Coll Cardiol. 2012 Feb 14;59(7):673-80
pubmed: 22322084
Eur Heart J Cardiovasc Imaging. 2017 Feb;18(2):119-127
pubmed: 27679598
J Am Soc Echocardiogr. 2016 Jun;29(6):537-44
pubmed: 27106009
J Am Coll Cardiol. 2014 Feb 18;63(6):493-505
pubmed: 24291276
JACC Cardiovasc Imaging. 2017 Jan;10(1):65-77
pubmed: 28057220
J Am Coll Cardiol. 2006 Jun 20;47(12):2357-63
pubmed: 16781359
N Engl J Med. 2013 Nov 28;369(22):2093-104
pubmed: 24251359
J Am Soc Echocardiogr. 2019 Feb;32(2):248-256
pubmed: 30316541
Am J Cardiol. 2012 Jul 15;110(2):264-9
pubmed: 22497676
Eur Heart J. 2013 Jan;34(4):278-85
pubmed: 22782941
J Cardiovasc Electrophysiol. 1998 Dec;9(12):1378-93
pubmed: 9869538
Eur Heart J. 2014 Jun 7;35(22):1457-65
pubmed: 24302269
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
J Am Soc Echocardiogr. 2014 Nov;27(11):1184-92
pubmed: 25260436
Circ Heart Fail. 2014 Nov;7(6):1042-9
pubmed: 25415957
N Engl J Med. 2018 Feb 01;378(5):417-427
pubmed: 29385358

Auteurs

Riccardo M Inciardi (RM)

Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Division of Cardiology, Department of Medicine, University Hospital of Verona, Verona, Italy.

Robert P Giugliano (RP)

TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Brian Claggett (B)

Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Deepak K Gupta (DK)

Vanderbilt Translational and Clinical Cardiovascular Research Center, Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

Alvin Chandra (A)

Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Christian T Ruff (CT)

TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Elliott M Antman (EM)

TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Michele F Mercuri (MF)

Cardiovascular, Metabolic and Renal Disease Therapeutic Area, Global Clinical Development, Daiichi Sankyo Pharma Development, Basking Ridge, NJ, USA.

Michael A Grosso (MA)

Cardiovascular, Metabolic and Renal Disease Therapeutic Area, Global Clinical Development, Daiichi Sankyo Pharma Development, Basking Ridge, NJ, USA.

Eugene Braunwald (E)

TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Scott D Solomon (SD)

Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH